PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$33.53
−0.15%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $2.3M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.81
- EPS estimate
- -$0.75
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +2.1%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $59
- PT range
- $44 – $79
- Analysts
- 9
9 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.75 | -$0.81 | Miss -8.48% | — |
| May 12, 2026 | -$0.82 | -$0.70 | Beat 14.83% | — |
| Nov 12, 2025 | -$0.78 | -$0.70 | Beat 10.26% | — |
| Aug 12, 2025 | -$0.87 | -$0.94 | Miss -8.05% | — |
| Mar 31, 2025 | — | -$0.93 | — | — |
| Aug 14, 2024 | -$0.57 | -$0.59 | Miss -3.51% | — |
| Apr 3, 2024 | -$0.58 | -$0.82 | Miss -41.38% | — |
| Nov 2, 2023 | -$0.67 | -$0.63 | Beat 5.97% | — |
| Apr 5, 2023 | — | -$0.73 | — | — |
| Dec 8, 2022 | -$0.64 | -$0.25 | Beat 60.94% | — |
| Jul 1, 2022 | — | -$0.39 | — | — |
| Jul 30, 2021 | -$0.51 | -$1.13 | Miss -121.57% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026